Lobaplatin, Paclitaxel, and Sintilimab Combination

The combination of lobaplatin, paclitaxel, and sintilimab appears to be an investigational treatment regimen that combines two chemotherapy agents (lobaplatin and paclitaxel) with an immune checkpoint inhibitor (sintilimab). While the search results don't specifically mention all three drugs used together in a single regimen, they do provide information about the individual components and various combinations. ## Components of the Combination **Lobaplatin** is a third-generation platinum antitumor agent with lower toxicity compared to earlier platinum compounds. It has been approved for treating breast cancer, small cell lung cancer, and chronic granulocytic leukemia[7]. **Paclitaxel**, particularly in its albumin-bound form (nab-paclitaxel), is a widely used chemotherapeutic agent that has shown efficacy in various cancers[1][2][3]. **Sintilimab** is a selective anti-PD-1 monoclonal antibody that has demonstrated efficacy in multiple cancer types. It was first approved for relapsed or refractory classical Hodgkin lymphoma after second-line chemotherapy[8]. ## Clinical Applications The search results indicate that various combinations of these drugs have been studied in different cancer types: - Sintilimab combined with nab-paclitaxel has shown promising efficacy in: - Severe lung squamous cell carcinoma[1] - Advanced cervical cancer[2] - Advanced or metastatic gastric cancer and gastroesophageal junction cancer[3] - Lobaplatin combined with paclitaxel has demonstrated efficacy in: - Squamous esophageal cancer as first-line chemotherapy[5] - Advanced gastric cancer (being compared with other regimens)[9] ## Mechanism of Action This combination would theoretically work through complementary mechanisms: 1. **Lobaplatin**: A platinum-based agent that forms DNA adducts, inhibiting DNA replication and transcription, leading to cell death[5][7]. 2. **Paclitaxel**: A taxane that stabilizes microtubules, preventing their disassembly and thereby disrupting cell division[1][2][3]. 3. **Sintilimab**: An anti-PD-1 antibody that blocks the interaction between PD-1 and its ligands (PD-L1/PD-L2), enhancing T-cell immune responses against tumor cells[6][8]. The combination of chemotherapy with PD-1 inhibitors has been shown to have synergistic effects in various cancer types[2][3], which provides a rationale for combining these three agents. While the specific triple combination of lobaplatin, paclitaxel, and sintilimab is not explicitly mentioned in the search results, the data suggests that such a combination might be effective in treating various solid tumors, particularly those that have shown response to platinum-based chemotherapy combined with immunotherapy.